Novel approaches to reduce temozolomide resistance in glioblastoma multiforme: a review of the literature
Temozolomide (TMZ), an oral alkylating agent, is currently used as a part of standard treatment for glioblastoma multiforme (GBM). GBM is considered one of the most lethal forms of human cancers, and despite recent improvement in cancer therapy, it remains an incurable disease, with a rare long-term...
Main Authors: | C. Jalili, I. Rashidi, M. Pazhouhi |
---|---|
Format: | Article |
Language: | English |
Published: |
Verduci Editore
2019-11-01
|
Series: | World Cancer Research Journal |
Subjects: | |
Online Access: | https://www.wcrj.net/wp-content/uploads/sites/5/2019/11/e1431-Novel-approaches-to-reduce-temozolomide-resistance-in-glioblastoma-multiforme-a-review-of-the-literature.pdf |
Similar Items
-
Meningeal seeding from glioblastoma multiforme treated with radiotherapy and temozolomide
by: Lu-Ting Kuo, et al.
Published: (2017-01-01) -
Fatal temozolomide induced aplastic anemia in a female with Glioblastoma multiforme : A case report and literature review
by: Fateen Ata, et al.
Published: (2021-03-01) -
Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
by: Yang He, et al.
Published: (2019-03-01) -
Hypofractionated Radiation Therapy with Temozolomide for Patients with Glioblastoma Multiforme Recursive Partitioning Analyzes Class V and VI
by: Fuzuli Tuğrul, et al.
Published: (2019-09-01) -
Quinacrine enhances temozolomide cytotoxicity in temozolomide-sensitive and -resistant glioblastoma cells
by: Pingde Zhang, et al.
Published: (2018-01-01)